Characterization of the endometrial MSC marker ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) in low- and high-grade endometrial carcinomas: loss of stromal expression in the invasive phenotypes

dc.contributor.authorRodríguez-Martínez, Aitor
dc.contributor.authorTrapero, Carla
dc.contributor.authorVidal, August
dc.contributor.authorPiulats, Josep M.
dc.contributor.authorGómez de Aranda Pulgarín, Inmaculada
dc.contributor.authorSévigny, Jean
dc.contributor.authorFernández Montolí, Ma. Eulalia
dc.contributor.authorPonce i Sebastià, Jordi
dc.contributor.authorMatias-Guiu, Xavier, 1958-
dc.contributor.authorMartín Satué, Mireia
dc.date.accessioned2021-11-08T15:35:50Z
dc.date.available2021-11-08T15:35:50Z
dc.date.issued2021-04-22
dc.date.updated2021-11-08T15:35:50Z
dc.description.abstractEctonucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) has been described in human non-pathological endometrium in both epithelial and stromal components without changes along the cycle. It was identified as a stromal marker of basalis. In the present study, we aimed to evaluate NTPDase2 distribution, using immunolabeling and in situ enzyme activity approaches, in endometrial carcinoma (EC) at different tumor grades. NTPDase2 was present in tumor epithelial EC cells, as in the non-pathological endometria, but the expression underwent changes in subcellular distribution and also tended to decrease with the tumor grade. In stroma, NTPDase2 was identified exclusively at the tumor-myometrial junction but this expression was lost in tumors of invasive phenotype. We have also identified in EC samples the presence of the perivascular population of endometrial mesenchymal stem cells (eMSCs) positive for sushi domain containing 2 (SUSD2) and for NTPDase2, already described in non-tumoral endometrium. Our results point to NTPDase2 as a histopathological marker of tumor invasion in EC, with diagnostic relevance especially in cases of EC coexisting with other endometrial disorders, such as adenomyosis, which occasionally hampers the assessment of tumor invasion parameters.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec712476
dc.identifier.issn2075-4426
dc.identifier.pmid33922226
dc.identifier.urihttps://hdl.handle.net/2445/181136
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jpm11050331
dc.relation.ispartofJournal of Personalized Medicine, 2021, vol. 11, num. 5, p. 331
dc.relation.urihttps://doi.org/10.3390/jpm11050331
dc.rightscc-by (c) Rodríguez-Martínez, Aitor et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCàncer d'endometri
dc.subject.classificationFenotip
dc.subject.classificationEpiteli
dc.subject.otherEndometrial cancer
dc.subject.otherPhenotype
dc.subject.otherEpithelium
dc.titleCharacterization of the endometrial MSC marker ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) in low- and high-grade endometrial carcinomas: loss of stromal expression in the invasive phenotypes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
712476.pdf
Mida:
10.55 MB
Format:
Adobe Portable Document Format